## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANG	SES IN BE	NEFICIAL	OWNERS	HIP

OMB APP	ROVAL
OMB Number:	3235-02

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

UNID APPR	OVAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

1. Name and Address of Reporting Person*					2. Issuer Name <b>and</b> Ticker or Trading Symbol EnteroMedics Inc [ ETRM ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
<u>Ansari Naqeeb A.</u>				1=	Enteromedies ine [ E1ton ]									Director	Director		10% Ov	vner					
-					-										$\dashv$ x		give title		Other (s	pecify			
(Last)	<b>(</b> E	irst)	(Middle)		3. 1	3. Date of Earliest Transaction (Month/Day/Year)								23	below)			below)	- 1				
` ′	•	*	(iviidule)		02	/08/2	2017									SVP of Sales							
2800 PA	TTON ROA	AD																		- 1			
																C. lasticidad as Jaiot/Ossus Filips (Obsala A. II. 1.)							
(0)						4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)		T. T.	EE44D												1 ′	Form fil	ad by Ona	Dana	utina Davas	.			
ST. PAU	L M	lN	55113												^	X Form filed by One Reporting Person							
-					-											Form filed by More than One Reporting							
(City)	(S	tate)	(Zip)													Person				- 1			
(0.0)			(=.p)																				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																						
1. Title of	Security (Inst	tr. 3)		2. Trans	sactio	action 2A. Deemed				3. 4. Securities Acquired (A)				(A) or	5. Amour				7. Nature of				
	, ,	•		Date	/D/D/			xecution Date,		Transac		Disposed Of (D) (Instr. 3, 4			3, 4 and				or Indirect   I	Indirect Beneficial			
				(Month	IDayiY	Day/Year) if any (Month/Day/Yea			Code (Inst		nstr.	5)				Beneficia Owned F				Ownership			
									",   <del>",                                      </del>					Reported	ed (''`			(Instr. 4)					
							Code V Amount		(A) or Price		Price	Transaction(s) (Instr. 3 and 4)				- 1							
				<u> </u>					-				- '	-,		(111541104							
Common	Stock															14	143(1)		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																						
																Owned							
			(	(e.g., p	outs,	, cai	ıs, warr	ants	s, o	ption	s, c	onvertik	ole s	ecurii	iles)								
1. Title of 2. 3. Transaction 3A. Deemed 4.							5. Number		6. E	Date Exe	rcisa	ble and	7. Tit	7. Title and Amo		8. Price of	9. Number of		10.	11. Nature			
Derivative	Conversion	Date	Execution D		Transa				Expiration Dat				of Securities		;	Derivative	derivative		Ownership				
Security (Instr. 3)									r)	Underlying Derivative Secu			Security (Instr. 5)	Securities Beneficially Owned Following Reported		Form: Direct (D)	Beneficial Ownership						
(1113111 0)											(1115111 0)	or Indirect	(Instr. 4)										
	Security (A) or												(I) (Instr. 4)			1							
	Disposed of (D) (Instr.													Transacti	on(s)		1						
						3, 4 and 5)											(Instr. 4)			1			
								Am					mount					1					
														0	r					1			
									Dat		Ι.				lumber					1			
				ا	Code	l۷	(A)	(D)		ie ercisable		Expiration Date	Title		hares					1			
							1, ,	H			+	-	1	_									
Stock Option													Com	mon									
(Right to	\$91.7 <sup>(1)</sup>								01/	19/2017 <sup>(</sup>	(2)	01/19/2026	Com		1,523		1,523 <sup>(</sup>	1)	D				
Buy)																							
Stock								Ш	_		$\top$							-		1			
Stock Option	47.40	02/02/2015			,		00.050				(3) L	22/00/00/2	Com	mon	,, ,,,,	*0.00	00.05	ا ر					
(Right to	\$7.12	02/08/2017			A		93,250		02/	08/2017 <sup>0</sup>		02/08/2027	Sto		3,250	\$0.00	93,25	υ	D				
D)																							

## **Explanation of Responses:**

- 1. On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value \$0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person, all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
- 2. Vests 25% one-year from the date of grant on the date noted and thereafter in cumulative installments of 1/36th per month.
- 3. Vests immediately as to 25% on the date noted and thereafter in cumulative installments of 1/36th per month.

EX 24: Ansari Power of Attorney Attached THIS FILING REFLECTS THE POST SPLIT NUMBERS OF ALL SHARES, OPTIONS AND SIMILAR INSTRUMENTS HELD BY THE REPORTING PERSON AS PREVIOUSLY REPORTED.

> /s/ Scott P. Youngstrom, 02/10/2017 <u>Attorney in Fact for Naqeeb A.</u> <u>Ansari</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that I hereby constitute and appoint each of Dan W. Gladney, Scott P. Youngstrom and Peter M. DeLange my true and lawful attorney-in-fact and agent, each acting alone, with full power of substitution for me and in my name, place and stead, to:

- execute for me and on my behalf, in my capacity as an officer and/or director of EnteroMedics Inc, Forms 3, 4 or 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder;
- 2. do and perform any and all acts for me and on my behalf which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto and timely file such Form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to me, in my best interest or legally required by me, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

I hereby grant to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as I might or could do if personally present, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. I acknowledge that the attorneys-in-fact, in serving in such capacity at my request, are not assuming, nor is EnteroMedics Inc. assuming, any of my responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until I am no longer required to file Forms 3, 4 and 5 with respect to my holdings of and transactions in securities of EnteroMedics Inc, unless earlier revoked by me in a signed writing delivered to the attorneys-in-fact named above.

IN WITNESS WHEREOF, I have signed this Power of Attorney on October 4,2016.

/s/ Naqeeb A. "Nick" Ansari Naqeeb A. "Nick" Ansari